PH12019500779A1 - Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin - Google Patents

Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Info

Publication number
PH12019500779A1
PH12019500779A1 PH12019500779A PH12019500779A PH12019500779A1 PH 12019500779 A1 PH12019500779 A1 PH 12019500779A1 PH 12019500779 A PH12019500779 A PH 12019500779A PH 12019500779 A PH12019500779 A PH 12019500779A PH 12019500779 A1 PH12019500779 A1 PH 12019500779A1
Authority
PH
Philippines
Prior art keywords
losartan
rosuvastatin
complex preparation
amlodipine
active ingredients
Prior art date
Application number
PH12019500779A
Inventor
Hyuk Jun Cho
Sol Ee Lim
Ho Taek Im
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12019500779(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PH12019500779A1 publication Critical patent/PH12019500779A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical complex preparation including amlodipine, losartan and rosuvastatin as active ingredients. The pharmaceutical complex preparation of the present invention including amlodipine, losartan and rosuvastatin as the active ingredients exhibits excellent dissolution characteristics of all the active ingredients, and also has improved preparation stability. Therefore, the complex preparation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has ensured quality stability even when stored for a long period of time.
PH12019500779A 2016-11-15 2019-04-11 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin PH12019500779A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160152077 2016-11-15
PCT/KR2017/012703 WO2018093096A2 (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Publications (1)

Publication Number Publication Date
PH12019500779A1 true PH12019500779A1 (en) 2019-07-29

Family

ID=62146632

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12019500779A PH12019500779A1 (en) 2016-11-15 2019-04-11 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Country Status (11)

Country Link
CO (1) CO2019004796A2 (en)
CR (1) CR20190265A (en)
DO (1) DOP2019000092A (en)
EA (1) EA201991190A1 (en)
EC (1) ECSP19040732A (en)
MX (1) MX2019005230A (en)
NI (1) NI201900048A (en)
PH (1) PH12019500779A1 (en)
SG (1) SG11201903132YA (en)
WO (1) WO2018093096A2 (en)
ZA (1) ZA201902720B (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007385A4 (en) * 2006-03-23 2010-08-18 Sinai School Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
KR101298788B1 (en) * 2011-03-15 2013-08-22 보령제약 주식회사 A combined formulation with improved stability
MX358211B (en) * 2012-07-23 2018-08-10 Landsteiner Scient S A De C V New differential-release pharmaceutical composition containing three active principles.
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR102369607B1 (en) * 2014-09-30 2022-03-03 한미약품 주식회사 Solid Pharmaceutical Composition Comprising Amlodipine and Losartan

Also Published As

Publication number Publication date
ECSP19040732A (en) 2019-07-31
NI201900048A (en) 2019-10-11
DOP2019000092A (en) 2019-09-30
SG11201903132YA (en) 2019-05-30
WO2018093096A2 (en) 2018-05-24
WO2018093096A3 (en) 2018-07-26
CO2019004796A2 (en) 2019-05-21
EA201991190A1 (en) 2019-10-31
CR20190265A (en) 2019-08-22
ZA201902720B (en) 2020-08-26
MX2019005230A (en) 2019-08-14

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2016014320A (en) Extended release suspension compositions.
PH12016502248A1 (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
MX2019015744A (en) Pharmaceutical compositions.
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12019500778A1 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2019012803A (en) New bicyclic pyrazole derivatives.
EA201791009A1 (en) COMPOSITIONS CONTAINING CYCLOSPORIN
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
MA39009A (en) Compositions pharmaceutiques comprenant un agent actif
GR20150100035A (en) Pharmaceutical aprepitant-containing formulation and preparation method thereof
PH12016502527B1 (en) Stabilized desmopressin
EA201891848A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS
MY194591A (en) Pharmaceutical combination formulation
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia